echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Targeted RNA-modified protein to treat leukemia with Ipsen reached over 400 million U.S. dollars in cooperation

    Targeted RNA-modified protein to treat leukemia with Ipsen reached over 400 million U.S. dollars in cooperation

    • Last Update: 2021-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On October 18, 2021, Ipsen and Accent Therapeutics announced that they have reached an exclusive global cooperation agreement to advance the research, development, manufacturing and commercialization of drugs targeting the RNA-modified protein METTL3

    Accent's new METL3 small molecule inhibitor is designed to treat specific subtypes of acute myeloid leukemia (AML) with high unmet medical needs

    AML is a difficult-to-treat blood and bone marrow cancer.
    Globally, the incidence of AML has been increasing year by year in the past 20 years

    RNA-modifying proteins (RMPs) are a class of emerging targets that represent a new strategy for the treatment of various cancers

    One of the most common modifications of mRNA is the methylation of the N6 adenine base to form N6-methyladenosine (m6A)

    The methyltransferase complex METL3/METTL14 catalyzes this modification process

    Image source: Accent's official website

    According to the terms of the cooperation agreement, Ipsen obtained the exclusive development rights for a METL3 small molecule inhibitor

    Accent may receive a total of US$446 million in advance payments, preclinical, clinical, regulatory and sales milestone payments, plus future royalties for tiered sales of the product

    Reference materials:

    [1] Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3.

    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.